MX2017010716A - Formulaciones en milicapsulas que comprenden acidos grasos libres poliinsaturados. - Google Patents

Formulaciones en milicapsulas que comprenden acidos grasos libres poliinsaturados.

Info

Publication number
MX2017010716A
MX2017010716A MX2017010716A MX2017010716A MX2017010716A MX 2017010716 A MX2017010716 A MX 2017010716A MX 2017010716 A MX2017010716 A MX 2017010716A MX 2017010716 A MX2017010716 A MX 2017010716A MX 2017010716 A MX2017010716 A MX 2017010716A
Authority
MX
Mexico
Prior art keywords
free fatty
fatty acids
polyunsaturated
polyunsaturated free
dosage forms
Prior art date
Application number
MX2017010716A
Other languages
English (en)
Inventor
Kubota Hironori
Thierry Charles ROGEAU Etienne
AMEMIYA Toru
Georges Meissonnier Julien
Gillis Holmén Anders
Radevik Andreas
Carlsson Hans
Staffan Schantz Bengt
Original Assignee
Omthera Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omthera Pharmaceuticals Inc filed Critical Omthera Pharmaceuticals Inc
Publication of MX2017010716A publication Critical patent/MX2017010716A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/009—Sachets, pouches characterised by the material or function of the envelope
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A61K9/5057—Gelatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En el presente documento se proporcionan formas de dosificación en cápsulas que contienen composiciones de ácidos grasos poliinsaturados (PUFA). En determinadas realizaciones, se proporcionan formas de dosificación unitaria que comprenden una serie de milicápsulas que comprenden en su interior una composición de PUFA así como sus métodos de uso y fabricación. En determinadas realizaciones, se proporcionan en el presente documento formas de dosificación en cápsulas que incluyen una forma de dosificación unitaria que comprende una diversidad de milicápsulas que contienen un ácido graso libre poliinsaturado sustancialmente en forma de ácido libre. En algunas realizaciones, la composición de PUFA es Epanova(r).
MX2017010716A 2015-02-23 2016-02-19 Formulaciones en milicapsulas que comprenden acidos grasos libres poliinsaturados. MX2017010716A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15305278 2015-02-23
PCT/US2016/018571 WO2016137825A1 (en) 2015-02-23 2016-02-19 Millicapsule formulations comprising polyunsaturated free fatty acids

Publications (1)

Publication Number Publication Date
MX2017010716A true MX2017010716A (es) 2018-03-16

Family

ID=52633188

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017010716A MX2017010716A (es) 2015-02-23 2016-02-19 Formulaciones en milicapsulas que comprenden acidos grasos libres poliinsaturados.

Country Status (16)

Country Link
US (1) US10512611B2 (es)
EP (1) EP3261622A4 (es)
JP (1) JP6469261B2 (es)
KR (2) KR20190090087A (es)
CN (1) CN107530284A (es)
AU (1) AU2016223109B2 (es)
CA (1) CA2975549C (es)
CL (1) CL2017002131A1 (es)
EA (1) EA035377B1 (es)
HK (1) HK1244218A1 (es)
IL (1) IL253697B (es)
MA (1) MA41611A (es)
MX (1) MX2017010716A (es)
NZ (1) NZ734149A (es)
WO (1) WO2016137825A1 (es)
ZA (1) ZA201705620B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2800563T3 (pl) 2012-01-06 2018-12-31 Omthera Pharmaceuticals Inc. Wzbogacone w DPA kompozycje wielonienasyconych kwasów tłuszczowych omega-3 w postaci wolnego kwasu
AU2018321407A1 (en) * 2017-08-25 2020-03-26 Struct Nutrition, Llc Compositions and methods for preventing, alleviating, and treating neurological injury following head trauma
CN109463762A (zh) * 2018-12-10 2019-03-15 瞿瀚鹏 Dha油脂组合物在软胶囊中的应用以及软胶囊及其制备方法
JP7315383B2 (ja) * 2019-06-27 2023-07-26 株式会社Ｓｃｒｅｅｎホールディングス インクジェット用水性組成物及び固体製剤
KR20230151363A (ko) * 2022-04-25 2023-11-01 유엠에스엔지니어링 주식회사 오메가 3 심리스 연질캡슐 제조방법

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59225115A (ja) * 1983-06-06 1984-12-18 Ota Seiyaku Kk 青魚類から得た長鎖高度不飽和脂肪酸を含有する微細カプセル
JPS61126016A (ja) 1984-11-22 1986-06-13 Toagosei Chem Ind Co Ltd 不飽和脂肪酸を内相物としたマイクロカプセル
DE4201178C2 (de) * 1992-01-17 1995-12-07 Alfatec Pharma Gmbh Verfahren zur Herstellung von Weichgelatinekapseln nach einem Tropfverfahren
JPH0753356A (ja) * 1993-08-16 1995-02-28 Morishita Jintan Kk 酸化され易い油性物質を内容物とするシームレスカプセルおよびその製造方法
GB9509764D0 (en) 1995-05-15 1995-07-05 Tillotts Pharma Ag Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
US5686106A (en) * 1995-05-17 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form for colonic delivery
WO2000021524A1 (en) * 1998-10-15 2000-04-20 Dsm N.V. Pufa supplements
WO2001015702A1 (fr) 1999-08-31 2001-03-08 Chugai Seiyaku Kabushiki Kaisha Capsules molles
US7025984B1 (en) 2000-06-26 2006-04-11 The Procter & Gamble Company Compositions and methods for body weight management
US20040217549A1 (en) * 2003-05-01 2004-11-04 Justak John F. Hydrodynamic brush seal
GB0403247D0 (en) 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
US7622137B2 (en) * 2004-05-21 2009-11-24 Accu-Break Technologies, Inc. Dosage forms contained within a capsule or sachet
CA2613474A1 (en) * 2005-06-20 2007-03-08 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds
CN101287382A (zh) * 2005-07-07 2008-10-15 加拿大海洋营养食品有限公司 含有输送装置的食物制品及其制造方法
US20070134493A1 (en) 2005-12-08 2007-06-14 Kanji Meghpara Compositions and capsules with stable hydrophilic layers
US20070141211A1 (en) * 2005-12-16 2007-06-21 Solae, Llc Encapsulated Phospholipid-Stabilized Oxidizable Material
CA2634139C (en) 2005-12-20 2015-06-23 Cenestra, Llc. Omega 3 fatty acid formulations
US20090304784A1 (en) 2006-07-28 2009-12-10 V. Mane Fils Seamless capsules containing high amounts of polyunsaturated fatty acids and a flavouring component
KR100758664B1 (ko) * 2006-08-16 2007-09-13 (주)케비젠 불포화지방산 함유 마이크로캡슐의 제조방법, 이 방법에의해 제조된 마이크로캡슐 및 이를 포함하는 제품
BRPI0816507A2 (pt) * 2007-10-17 2014-10-07 Unilever Nv "produto comestível, processo para a preparação de uma cápsula revestida e uso de um produto comestível"
US20100285121A1 (en) 2008-01-10 2010-11-11 Takeda Pharmaceutical Company Limited Capsule Formulation
US20100062057A1 (en) * 2008-09-10 2010-03-11 Pronova BioPharma Norge AS. Formulation
ES2578081T5 (es) 2009-05-01 2019-10-16 Uas Laboratories Llc Composiciones bacterianas para profilaxis y tratamiento de enfermedades degenerativas
KR20200013123A (ko) * 2009-10-23 2020-02-05 바스프 에이에스 지방산 오일 혼합물의 코팅된 캡슐 및 정제
EP2717575B1 (en) * 2011-05-27 2018-10-10 Sun Patent Trust Image decoding method and image decoding device
JP2013084557A (ja) * 2011-07-21 2013-05-09 Rohm Co Ltd 照明装置
WO2013040507A1 (en) 2011-09-15 2013-03-21 Omthera Pharmaceuticals, Inc. Methods and compositions for treating, reversing, inhibiting or preventing resistance to antiplatelet therapy
WO2013059669A1 (en) 2011-10-21 2013-04-25 Omthera Pharmaceuticals, Inc. Methods and compositions for treating or preventing attention deficit hyperactivity disorder
PL2800563T3 (pl) * 2012-01-06 2018-12-31 Omthera Pharmaceuticals Inc. Wzbogacone w DPA kompozycje wielonienasyconych kwasów tłuszczowych omega-3 w postaci wolnego kwasu
IL249821B (en) * 2012-03-30 2019-04-30 Sancilio & Company Inc Omega-3 fatty acid ester compositions
JP6173437B2 (ja) 2012-05-07 2017-08-02 オムセラ・ファーマシューティカルズ・インコーポレイテッド スタチン及びω−３脂肪酸の組成物
SG10202104627UA (en) * 2013-12-13 2021-06-29 Novartis Ag Pharmaceutical dosage forms
CN103989666A (zh) * 2014-04-11 2014-08-20 浙江海洋学院 n-3多不饱和脂肪酸在治疗非酒精性脂肪肝病药物中的应用
WO2016069446A1 (en) 2014-10-28 2016-05-06 Omthera Pharmaceuticals Inc Methods for modulating plasma levels of lipoproteins
WO2016073335A1 (en) 2014-11-05 2016-05-12 Omthera Pharmaceuticals Inc. Methods of treatment
WO2016130417A1 (en) 2015-02-11 2016-08-18 Omthera Pharmaceuticals Inc Omega-3 fatty acid prodrug compounds and uses thereof

Also Published As

Publication number Publication date
WO2016137825A1 (en) 2016-09-01
CA2975549A1 (en) 2016-09-01
CA2975549C (en) 2019-04-02
AU2016223109A1 (en) 2017-08-17
EA201791766A1 (ru) 2018-03-30
AU2016223109B2 (en) 2018-10-04
EP3261622A4 (en) 2018-12-19
JP6469261B2 (ja) 2019-02-13
NZ734149A (en) 2018-08-31
MA41611A (fr) 2018-01-02
US10512611B2 (en) 2019-12-24
CN107530284A (zh) 2018-01-02
JP2018505914A (ja) 2018-03-01
WO2016137825A8 (en) 2017-08-31
IL253697B (en) 2020-08-31
EP3261622A1 (en) 2018-01-03
ZA201705620B (en) 2019-06-26
EA035377B1 (ru) 2020-06-03
KR20170116153A (ko) 2017-10-18
HK1244218A1 (zh) 2018-08-03
US20180325829A1 (en) 2018-11-15
KR20190090087A (ko) 2019-07-31
IL253697A0 (en) 2017-09-28
CL2017002131A1 (es) 2018-04-13

Similar Documents

Publication Publication Date Title
CL2019002663A1 (es) Producción de ácidos grasos poliinsaturados de cadena larga en células vegetales. (divisional solicitud 201702448)
MY165048A (en) Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
NZ734149A (en) Millicapsule formulations comprising polyunsaturated free fatty acids
MX2016004487A (es) Capsulas blandas de capa entérica que constan de ácidos grasos poli insaturados.
PH12016500216B1 (en) Stable pharmaceutical composition and methods of using same
NZ702325A (en) Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors
PE20180456A1 (es) Acidos grasos poliinsaturados de cadena muy larga a partir de aceites naturales
MX342216B (es) Composiciones de acidos grasos.
PH12018500410A1 (en) Refined oil compositions and methods for making
IL276596A (en) Polyunsaturated fatty acids, monoglycerides, compounds, methods and use thereof
SA515361092B1 (ar) تركيبات راسكادوتريل الدهنية
MY198214A (en) Fatty acid composition and use thereof
MY195213A (en) Release Agent Composition
GEP201606568B (en) Compositions for the treatment of neurologic disorders
NZ747847A (en) Lipid compositions
WO2014165190A3 (en) Compositions comprising docosapentaenoic acid and methods of use
ZA202107552B (en) Cannabinoids compositions with polyunsaturated fatty acid monoglycerides, methods and uses thereof
MX2018004128A (es) Composiciones de aceite y metodos para elaborarlas.
PL3346980T3 (pl) Lipofilowe kompozycje kosmetyczne zawierające estry kwasu pelargonowego
MX2014009404A (es) Composiciones de dispersion de acidos grasos saturados y trans reducidos.
MY201533A (en) Palm-based wax composition
MX2015016410A (es) Esteres de acidos oligo-hidroxicarboxilicos y uso de los mismos.
BR112016028561A8 (pt) composição e forma de dosagem compreendendo um óleo marinho que compreende ácidos graxos, e, uso das mesmas
PL3560342T3 (pl) Kompozycje wielonienasyconych kwasów tłuszczowych wzbogacone w dha
PH12018502207A1 (en) Methods of manufacturing nutritional formulations